STRATA Skin Sciences Inkomsten in het verleden
Verleden criteriumcontroles 0/6
STRATA Skin Sciences's earnings have been declining at an average annual rate of -24.6%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 5% per year.
Belangrijke informatie
-24.6%
Groei van de winst
-23.0%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 5.0% |
| Rendement op eigen vermogen | -87.6% |
| Nettomarge | -25.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%
Aug 18
Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?
Aug 07STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business
Jun 07Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?
Mar 19STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 31Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?
Nov 03We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt
Jul 04STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company
Apr 18Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?
Jan 14STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M
Aug 10Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment
Jul 25What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 09Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years
Nov 24
STRATA Skin Sciences EPS in-line, beats on revenue
Nov 10Opbrengsten en kosten
Hoe STRATA Skin Sciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 33 | -8 | 22 | 1 |
| 31 Mar 24 | 33 | -11 | 23 | 1 |
| 31 Dec 23 | 33 | -11 | 23 | 1 |
| 30 Sep 23 | 35 | -7 | 24 | 1 |
| 30 Jun 23 | 36 | -7 | 25 | 1 |
| 31 Mar 23 | 37 | -6 | 26 | 1 |
| 31 Dec 22 | 36 | -6 | 25 | 1 |
| 30 Sep 22 | 35 | -6 | 25 | 1 |
| 30 Jun 22 | 33 | -6 | 25 | 1 |
| 31 Mar 22 | 31 | -3 | 23 | 1 |
| 31 Dec 21 | 30 | -3 | 23 | 1 |
| 30 Sep 21 | 28 | -2 | 21 | 1 |
| 30 Jun 21 | 26 | -3 | 20 | 2 |
| 31 Mar 21 | 22 | -6 | 18 | 1 |
| 31 Dec 20 | 23 | -4 | 17 | 1 |
| 30 Sep 20 | 25 | -4 | 18 | 1 |
| 30 Jun 20 | 27 | -4 | 19 | 1 |
| 31 Mar 20 | 31 | -3 | 22 | 1 |
| 31 Dec 19 | 32 | -4 | 22 | 1 |
| 30 Sep 19 | 31 | -3 | 21 | 1 |
| 30 Jun 19 | 31 | -3 | 21 | 1 |
| 31 Mar 19 | 31 | -3 | 20 | 1 |
| 31 Dec 18 | 30 | -4 | 19 | 1 |
| 30 Sep 18 | 31 | -9 | 20 | 1 |
| 30 Jun 18 | 30 | -22 | 19 | 1 |
| 31 Mar 18 | 31 | -21 | 19 | 2 |
| 31 Dec 17 | 32 | -22 | 19 | 2 |
| 30 Sep 17 | 30 | -18 | 17 | 2 |
| 30 Jun 17 | 31 | -6 | 18 | 2 |
| 31 Mar 17 | 30 | -4 | 19 | 2 |
| 31 Dec 16 | 31 | -3 | 20 | 2 |
| 30 Sep 16 | 33 | -3 | 23 | 2 |
| 30 Jun 16 | 33 | -14 | 24 | 3 |
| 31 Mar 16 | 26 | -22 | 22 | 2 |
| 31 Dec 15 | 18 | -28 | 19 | 2 |
| 30 Sep 15 | 9 | -34 | 15 | 2 |
| 30 Jun 15 | 1 | -24 | 11 | 1 |
| 31 Mar 15 | 1 | -15 | 11 | 1 |
| 31 Dec 14 | 1 | -16 | 11 | 2 |
| 30 Sep 14 | 1 | -14 | 11 | 2 |
| 30 Jun 14 | 1 | -19 | 13 | 2 |
| 31 Mar 14 | 0 | -27 | 14 | 3 |
| 31 Dec 13 | 1 | -26 | 16 | 4 |
Kwaliteitswinsten: SSKN is currently unprofitable.
Groeiende winstmarge: SSKN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SSKN is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.
Versnelling van de groei: Unable to compare SSKN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SSKN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Rendement op eigen vermogen
Hoge ROE: SSKN has a negative Return on Equity (-87.55%), as it is currently unprofitable.